

Pursuant to the provisions of article 228 of the Consolidated Text of the Securities Market Act, approved by the Legislative Royal Decree 4/2015, of 23 October, Grifols, S.A. ("Grifols") hereby informs about the following

RELEVANT EVENT

Grifols has entered into an agreement with Chinese based Jiangxi Boya Bio-Pharmaceutical Co. Ltd. whereby both parties have agreed to jointly collaborate to build and manage a significant number of plasma collection centres throughout the territory of the People's Republic of China.

In accordance with current applicable laws, all collected plasma by the collection centres built under this project will be supplied to Boya. This notwithstanding, Grifols has reserved the right to have access to up to 50% of the collected plasma by each plasma collection centre, if and when permitted by applicable laws.

The initial investment for the project is EUR 50 million.

In Barcelona, on 10 May 2018

Nuria Martín Barnés
Secretary to the Board of Directors